王倩. 重庆市大足区20202021年商业保险机制在预防接种异常反应中的应用[J]. 上海预防医学, 2022, 34(9): 930-934. DOI: 10.19428/j.cnki.sjpm.2022.21995
引用本文: 王倩. 重庆市大足区20202021年商业保险机制在预防接种异常反应中的应用[J]. 上海预防医学, 2022, 34(9): 930-934. DOI: 10.19428/j.cnki.sjpm.2022.21995
WANG Qian. Analysis of the application of commercial insurance mechanism in abnormal vaccination responses in Dazu District of Chongqing City in 2020‒2021[J]. Shanghai Journal of Preventive Medicine, 2022, 34(9): 930-934. DOI: 10.19428/j.cnki.sjpm.2022.21995
Citation: WANG Qian. Analysis of the application of commercial insurance mechanism in abnormal vaccination responses in Dazu District of Chongqing City in 2020‒2021[J]. Shanghai Journal of Preventive Medicine, 2022, 34(9): 930-934. DOI: 10.19428/j.cnki.sjpm.2022.21995

重庆市大足区20202021年商业保险机制在预防接种异常反应中的应用

Analysis of the application of commercial insurance mechanism in abnormal vaccination responses in Dazu District of Chongqing City in 2020‒2021

  • 摘要:
    目的 分析重庆市大足区预防接种异常反应商业保险的实施情况。
    方法 收集2020—2021重庆市大足区年疑似预防接种异常反应(adverse events following immunization,AEFI)个案、疫苗接种数据、商业保险补偿信息,采用描述性流行病学方法进行分析。
    结果 2020—2021年,重庆市大足区共接种72 341人、328 685剂次,接种免疫规划疫苗68 669人、非免疫规划疫苗24 551人,接种剂次数最多达28剂次/人,商业保险中基础保险在免疫规划疫苗中覆盖率为100%,商业补充保险覆盖率较低,仅有1.61%,≤12月龄的覆盖率也仅有5.99%;2020—2021年AEFI原有监测报告发生率为29.21/10万,增加商业保险报告途径后报告发生率增长到43.20/10万,差异有统计学意义(χ2=8.894,P<0.05);补充保险对46例偶合反应共补偿148 544.81元,其中有86.21%在7 d内完成了赔付。
    结论 开展预防接种异常反应商业保险是有必要的,需持续推进预防接种异常反应保险补偿工作。

     

    Abstract:
    Objective To analyze the implementation of commercial insurance for abnormal reactions from vaccination in Dazu District of Chongqing City.
    Methods Suspected adverse events following immunization (AEFI) cases, vaccination data and commercial insurance compensation information in Dazu District from 2020 to 2021 were collected and analyzed by the descriptive epidemiological method.
    Results From 2020 to 2021, a total of 72 341 people received 328 686 doses of vaccines, including 68 668 people who received vaccines under the National Immunization Program (NIP) and 24 551 people who received non-NIP vaccines. The maximum number of vaccines reached 28 doses per person. Among commercial insurance schemes, the coverage rate of basic insurance in NIP vaccines was 100%, while the coverage rate of commercial supplementary insurance was only 1.61%, and the coverage rate for children below 12 months was only 5.99%. From 2020 to 2021, the reported AEFI incidence through the existing surveillance system was 29.21/10-5, which increased to 43.20/10-5 after commercial insurance reporting was added, and the difference was statistically significant (χ2=8.894, P<0.05). The total compensation of commercial supplementary insurance for 46 cases of coincidental events was 148 544.81 yuan, and 86.21% of the compensation cases were paid within 7 days.
    Conclusion Commercial insurance is necessary for abnormal reactions to vaccination, and the insurance compensation for abnormal reactions to vaccination should be continuously promoted.

     

/

返回文章
返回